Title |
Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes
|
---|---|
Published in |
Molecular Cancer, October 2017
|
DOI | 10.1186/s12943-017-0726-4 |
Pubmed ID | |
Authors |
Marta Rodríguez, Cristina Bajo-Santos, Nina P. Hessvik, Susanne Lorenz, Bastian Fromm, Viktor Berge, Kirsten Sandvig, Aija Linē, Alicia Llorente |
Abstract |
The aim of this study was to identify microRNAs in urinary exosomes that are differently expressed in prostate cancer patients and healthy donors. For this purpose, RNA was extracted from urinary exosomes from 20 prostate cancer patients and 9 healthy males and the microRNAs were analyzed by next generation sequencing. Interestingly, 5 microRNAs - miR-196a-5p, miR-34a-5p, miR-143-3p, miR-501-3p and miR-92a-1-5p - were significantly downregulated in exosomes from prostate cancer patients. Furthermore, RT-qPCR analysis of an independent cohort of 28 prostate cancer patients and 19 healthy males confirmed that miR-196a-5p and miR-501-3p were downregulated in prostate cancer samples. These results suggest that specific microRNAs in urinary exosomes might serve as non-invasive biomarkers for prostate cancer. In particular, miR-196a-5p and miR-501-3p are promising biomarkers that need to be further studied in large patient cohorts. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 105 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 15 | 14% |
Student > Bachelor | 14 | 13% |
Researcher | 12 | 11% |
Student > Master | 12 | 11% |
Student > Doctoral Student | 10 | 10% |
Other | 14 | 13% |
Unknown | 28 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 32 | 30% |
Medicine and Dentistry | 12 | 11% |
Agricultural and Biological Sciences | 9 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
Computer Science | 3 | 3% |
Other | 8 | 8% |
Unknown | 37 | 35% |